Tyra Biosciences Inc (NASDAQ: TYRA) has experienced a rise in its stock price by 10.97 compared to its previous closing price of 20.15. However, the company has seen a gain of 4.24% in its stock price over the last five trading days. accesswire.com reported 2024-09-12 that LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or “the Company”) (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Is It Worth Investing in Tyra Biosciences Inc (NASDAQ: TYRA) Right Now?
Company’s 36-month beta value is 1.03.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TYRA is 26.61M, and currently, short sellers hold a 8.51% ratio of that floaft. The average trading volume of TYRA on September 18, 2024 was 163.37K shares.
TYRA’s Market Performance
TYRA’s stock has seen a 4.24% increase for the week, with a 2.85% rise in the past month and a 25.97% gain in the past quarter. The volatility ratio for the week is 7.82%, and the volatility levels for the past 30 days are at 6.00% for Tyra Biosciences Inc The simple moving average for the past 20 days is 3.93% for TYRA’s stock, with a 28.24% simple moving average for the past 200 days.
Analysts’ Opinion of TYRA
Many brokerage firms have already submitted their reports for TYRA stocks, with Piper Sandler repeating the rating for TYRA by listing it as a “Overweight.” The predicted price for TYRA in the upcoming period, according to Piper Sandler is $33 based on the research report published on August 15, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see TYRA reach a price target of $15, previously predicting the price at $25. The rating they have provided for TYRA stocks is “Neutral” according to the report published on December 15th, 2023.
Wedbush gave a rating of “Outperform” to TYRA, setting the target price at $27 in the report published on June 30th of the previous year.
TYRA Trading at 7.43% from the 50-Day Moving Average
After a stumble in the market that brought TYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.79% of loss for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 7.82%, as shares surge +1.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.76% upper at present.
During the last 5 trading sessions, TYRA rose by +4.24%, which changed the moving average for the period of 200-days by +102.35% in comparison to the 20-day moving average, which settled at $21.53. In addition, Tyra Biosciences Inc saw 61.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TYRA starting from Bensen Daniel, who sale 3,502 shares at the price of $20.00 back on Jun 10 ’24. After this action, Bensen Daniel now owns 427,981 shares of Tyra Biosciences Inc, valued at $70,045 using the latest closing price.
Bensen Daniel, the Chief Operating Officer of Tyra Biosciences Inc, sale 200 shares at $20.00 during a trade that took place back on Jun 07 ’24, which means that Bensen Daniel is holding 431,483 shares at $4,000 based on the most recent closing price.
Stock Fundamentals for TYRA
Current profitability levels for the company are sitting at:
- -190.14 for the present operating margin
- 0.14 for the gross margin
The net margin for Tyra Biosciences Inc stands at -161.11. The total capital return value is set at -0.25. Equity return is now at value -26.32, with -25.18 for asset returns.
Based on Tyra Biosciences Inc (TYRA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -9.84. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -38.9.
Currently, EBITDA for the company is -79.59 million with net debt to EBITDA at 0.98. When we switch over and look at the enterprise to sales, we see a ratio of 2163.54. The receivables turnover for the company is 0.26for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 36.46.
Conclusion
In a nutshell, Tyra Biosciences Inc (TYRA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
